Rubicon Research Delivers Robust Q2 FY27 With Strong Growth Across Operating Metrics
Rubicon Research Ltd · Investor Presentation · 05 Nov 2026, 9:39 pm
Rubicon Research Delivers Robust Q2 FY27 With Strong Growth Across Operating Metrics Rubicon Research reported Q2 FY27 revenue from operations of ₹5,764 Mn, up 39.9% YoY and 7.9% QoQ ($58 Mn, up >5% QoQ). EBITDA rose 54.1% YoY to ₹1,464 Mn with margins expanding 230 bps YoY to 25.4%, while PAT jumped 67.9% YoY to ₹904 Mn. Driven by strong momentum, management raised FY27 operating EBITDA margin guidance to 24%+ (from 23%+). Specialty products contributed 36% of gross profit, backed by an 84% US commercialization rate across 90 approved products.
Original exchange filing (PDF)
More announcements from Rubicon Research Ltd
- Disclosure under Regulation 30 of SEBI LODR Regulations, 2015 (SEBI Regulations) w.r.t update on the Scheme of Merger between Rubicon Research Ltd and KIA Health Tech Pvt Ltd · 14 Nov 2026
- Transcript of Earnings Call -Q2 - FY 2026-27 · 12 Nov 2026
- Audio Recording of Earnings confrence call for the Quarter ended 30th September, 2026 · 06 Nov 2026
- Monitoring Agency Report - Q2 ended September 2026 · 05 Nov 2026
- Rubicon Research Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held on November 5, 2026 · 05 Nov 2026
- Grant of Stock Options under Rubicon Research LImited Stock Option Plan 2026 · 05 Nov 2026
- Outcome of USFDA Inspection of Rubicon Research Ltd Manufactiring Facility at Ambernath, India · 30 Oct 2026
